Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 18/07/2024 am IST			After market 05:29:54 am
905.6 ^USD	-3.82%		918	+1.37%

17/07	Global markets live: Adidas, TSMC, Vale, HSBC, J&J...
17/07	Stocks to watch as Biden, Trump vie for presidency	RE

Eli Lilly and Company Reports Earnings Results for the Fourth Quarter Ended December 31, 2020

January 29, 2021 at 05:03 pm IST

Eli Lilly and Company announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced sales was USD 7,440 million compared to USD 6,114 million a year ago. Operating income was USD 1,992.1 million compared to USD 1,400.2 million a year ago. Net income was USD 2,116.8 million compared to USD 1,495.7 million a year ago. Diluted earnings per share was USD 2.32 compared to USD 1.64 a year ago.

Latest news about Eli Lilly and Company

Global markets live: Adidas, TSMC, Vale, HSBC, J&J...	17/07
Stocks to watch as Biden, Trump vie for presidency	17/07	RE
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850	17/07	MT
Earnings reports take center stage as tech stocks tumble	17/07
Wall Street set to fall as megacap chip, tech stocks tumble	17/07	RE
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly...	17/07
Roche reports positive early results in obesity drug trial	17/07	RE
Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly	17/07	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793	16/07	MT
Novo owner backs Swiss biotech Asceneuron in $100 million round	16/07	RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	12/07	RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	12/07	MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating	12/07	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	12/07	RE
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	12/07	DJ
Pfizer moves forward with once-daily weight loss drug	11/07	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	11/07	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	11/07	MT
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating	11/07	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	11/07	RE
SANDERS SAYS HE IS CURRENTLY FOCUSED ON NOVO NORDISK BUT WILL 'C…	11/07	RE
Eli Lilly Names Gordon Brooks Interim Chief Financial Officer	10/07	DJ
Eli Lilly Appoints Gordon Brooks Interim CFO	10/07	MT
Barclays Adjusts Price Target on Eli Lilly to $1,025 From $913	10/07	MT

Chart Eli Lilly and Company

Duration

Period

More charts

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 13, 2024 at 12:17 am IST

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

905.6 USD

Average target price

901.5 USD

Spread / Average Target

-0.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B
SANOFI	+2.52%	125B

Other Pharmaceuticals